U.S. cancer survivors face economic burdens due to growing medical costs, productivity losses

NewsGuard 100/100 Score

U.S. cancer survivors face significant economic burdens due to growing medical costs, missed work, and reduced productivity, according to a study by the Centers for Disease Control and Prevention in today's Morbidity and Mortality Weekly Report.

"Cancer survivors face physical, emotional, psychosocial, employment and financial challenges as a result of their cancer diagnosis and treatment," said Donatus U. Ekwueme, PhD, a senior health economist at CDC's Division of Cancer Prevention and Control. "With the number of cancer survivors expected to increase by more than 30 percent in the next decade – to 18 million Americans -- medical and public health professionals must be diligent in their efforts to help reduce the burden of cancer on survivors and their families."

Researchers analyzed data from the Agency for Healthcare Research and Quality's 2008-2011 Medical Expenditure Panel Survey to estimate annual medical costs and productivity losses among male and female cancer survivors, aged 18 years and older, and among persons without a cancer diagnosis. Lost productivity was estimated by reviewing employment disability (being unable to work because of illness or injury), health-related missed work days, and days spent in bed due to ill health.

From 2008-2011, male cancer survivors had annual medical costs of more than $8,000 per person, and productivity losses of $3,700 compared to males without a history of cancer at $3,900 and $2,300 respectively. During the same time, female cancer survivors had $8,400 in annual medical costs per person and $4,000 in productivity losses compared to females without a history of cancer at $5,100 and $2,700, respectively.

Study findings indicate:

  • Cancer survivors were more likely to be female, non-Hispanic white, have multiple chronic conditions, or to be in fair or poor health.
  • Employment disability accounted for about 75 percent of lost productivity among cancer survivors.
  • Among survivors who were employed at the time of their diagnosis, cancer and its treatment interfered with physical tasks (25 percent) and mental tasks required by the job (14 percent); almost 25 percent of cancer survivors felt less productive at work.

The report also found that about 10 percent of survivors aged 65 years and younger were uninsured and likely to have a larger financial burden compared to survivors with some source of payment for medical services. Through the Affordable Care Act, millions of Americans, including cancer survivors, have access to health coverage and preventive services. For more information, please visit www.healthcare.gov.

The authors noted that nearly 32 percent of survivors experienced limitations in their usual daily activities outside of work because of cancer. Among those employed, more than 42 percent had to make changes to their work hours and duties. Comprehensive health and employment intervention programs may be needed to improve outcomes for cancer survivors and their families.

The findings in this report support data released in a recent CDC study about the significant financial challenges experienced by survivors of adolescent and young adult cancers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy